This afternoon we watched Natera drop -2.3% to a price of $51.77 per share. The mid-cap Medical Specialities company is now trading -31.37% below its average target price of $75.43. Analysts have set target prices ranging from $29.0 to $117.0 per share for Natera, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 5.7%, and a short ratio of 3.48. Since 3.38% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 96.7% of Natera's shares being owned by this investor type.
Institutions Invested in Natera
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2022-12-31 | Vanguard Group, Inc. (The) | 9% | 9,945,514 | $514,829,526 |
| 2022-12-31 | Fred Alger Management, LLC | 8% | 8,972,823 | $464,478,177 |
| 2022-12-31 | JP Morgan Chase & Company | 5% | 6,202,712 | $321,083,382 |
| 2022-12-31 | Blackrock Inc. | 5% | 5,566,939 | $288,172,593 |
| 2022-12-31 | Samlyn Capital, LLC | 4% | 4,390,372 | $227,267,603 |
| 2022-12-31 | State Street Corporation | 3% | 3,572,262 | $184,918,140 |
| 2022-12-31 | Sofinnova Investments, Inc. | 3% | 3,100,560 | $160,500,486 |
| 2022-12-31 | Citadel Advisors Llc | 3% | 3,048,948 | $157,828,791 |
| 2022-12-31 | Norges Bank Investment Management | 2% | 2,780,428 | $143,928,853 |
| 2022-12-31 | Eversept Partners, LP | 2% | 2,685,959 | $139,038,665 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Natera.
